Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Sweet sensors lecture 8 resources
1. Sweet Sensors
Small form factor Types of targets
diagnostic devices that
can detect a variety of • Recreational drugs
biological markers. • Heavy metals
• Toxins
• Inexpensive • Bacteria
• Quantitative • Viruses
• Adaptable to many • Pharmaceuticals
kinds of tests (targets) • Environmental hazards
• Food safety targets
Yu Xiang and Yi Lu, Nature Chem. 3, 697-703 (2011).
2. Meetings/Conversations From the Past Week
• Tecan group
– Global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics, and
clinical diagnostics.
• Teleconference with Director
of Strategic Alliances and three of her associates
in a major pharmaceutical company
• Abbott
• Director of Economic & Technical Development
Zone, Shanghai China
• Food Safety and Quality Conference
• Dr. Bill Olson, Market Medical Director - Pacific
Region United Healthcare
3. Upcoming Conversations
• Sword Diagnostics
• Abbott Labs
• Blue Cross Blue Shield innovation team
• Retired Hospital executive
• Biotech entrepreneur
• Michael Rosen, life sciences entrepreneur
and executive
• Other VCs
4. Key findings:
• Big pharma company is interested in low cost
drug monitoring during clinical trials and after the
drugs are approved to ensure safety and
effectiveness of the drug to individual patients
– Site visit in December
• Work with glucose meter manufacturers
– Our technology makes a particular glucose meter
more competitive on the market
• Look for biomarkers for diseases that associated
with diabetes
• Invitation to give a presentation @Abbott in
December
• Emergency room, rapid toxicology screen
5. Business Model Canvas # 8
Yi Lu, Tian Lan, Brian Wong
Sweet Sensors Neil Kane 11-15-2011
Chris Sorensen
Conferences
R&D
Pharmaceutical Immediate results Pharmaceutical
companies Publicity companies
Direct
Convenient monitoring
Diagnostics Insurance Reimbursement and safer dosage Long term
companies Diagnostic
Robust/extensible companies
Contract research
organizations
Inexpensive Contract research
organizations
Simple Pharmaceutical Cos
IP Investors
Glucometer mfr Personnel
Pharmaceutical Cos
Strip mfr
Licensing Licensing?
R&D Product Sales
6. Partners
• As noted on the Business Model Canvas, key
partners are pharmaceutical companies and
glucose meter manufacturers.
Sweet Sensors
Glucose meter Pharmaceutical /
manufacturer • Added value for meter diagnostic companies
• Meter engineering manufacturers • Provide the target of
• Strip design • Low cost, fast interest
• FDA approval monitoring improves • Key customers
clinical trials • Key market knowledge
7. Action plan
• Put together a compelling
presentation and go pitch
pharmaceutical
companies and diagnostic
companies. We’re getting
inconclusive results talking
to KOLs and consultants.
• We are on second revision
of a pitch to use.
8. Sweet Sensor Revenue Model
Factors
COPD MARKET All Segments
Market Size 16,000,000
Revenue Model
Market Share Target 10%
Channel Capacity 100%
Customer Activations 1,600,000
Attrition 10%
Net Customers 1,440,000
Missing: Revenue Model
Usage per Year 52
Lifetime value of customer Number of Uses per Year
Revenue per Use $4
74,880,000
$4
and amortization of Total revenue $299,520,000
acquisition costs over EXPENSES
Cost Per Customer Acquisition $25 $25
lifetime Cust. Acquisiiton Expense $40,000,000
Channel Split 30% 30%
Cost of Channel Sales $89,856,000
COGS $0.25 $18,720,000
Net Operating Income $150,944,000
Operating Margin 50%
Operating Expenses
GSA $5,000,000
EBIDTA $145,944,000
Net Margin 49%
9. Service Channel Distribution Model
Payment
Insurance Doctor
Company
Medical
Payment Services
Data
Service
Service Provider Patient
“Healthways”
In House Care
Services
Payment
Sweet
Sensors
Notas do Editor
Team introduction, glucose meter for detection of targets other than glucose; a device/strip to use with a glucometer for detection of non-glucose targets.
the old days of one wonder drug to cure all patients is gone and most pharmaceutical company is facing drugs are safe and effective to only certain populations. Therefore close and daily monitoring of therapeutic drugs is required.